Randomized control trials (DEPICT‐1 and DEPICT‐2) showed that adding dapagliflozin to the insulin therapy of adults with T1DM improved glycemic control without insulin‐related side effects [34, 35]. The gene discussed is INS; the disease is type 1 diabetes mellitus.